Evaluation Results and Recommendations of a Novel Tricuspid Regurgitation Classification for Isolated Tricuspid Valve Replacement Surgery
DOI:
https://doi.org/10.59958/hsf.7423Keywords:
tricuspid valve regurgitation, tricuspid valve replacement surgery, classificationAbstract
Background: There are still no accepted classification and recommendations for isolated tricuspid valve replacement (ITVR) surgery. So we aim to evaluate the applicability of the tricuspid valve regurgitation classification proposed by Latib in 2018 for ITVR surgery. Methods: We enrolled all patients who underwent ITVR from 2000 to 2021 in our center. Based on a novel classification, the patients were divided into five stages, and in-hospital mortality was used as the primary endpoint to analyze whether this classification scheme was a good way to evaluate the prognosis of patients at different stages and with different surgical options. Results: A total of 254 patients who underwent ITVR were divided into five stages. None of the patients was classified into stage 1, and stages 4/5 accounted for 159 (62.6%). There was no difference in age, gender, or body mass index (BMI). 178 (70.1%) patients underwent traditional open surgery and 76 (29.9%) opted for the transcatheter option. The main etiology was functional tricuspid regurgitation (FTR), with 64.9% of these patients in stage 4 or above. The overall in-hospital mortality rate was 14.2%, with 14.0% in stage 4 vs. 37.8% in stage 5 (p < 0.001). The patients in the intervention group were generally older, and coronary heart disease and atrial fibrillation were also more common (p < 0.05). Interventional mortality for stages 4 and 5 was 35.8% vs. 13.2% in the open group, but there was no significant difference between them after propensity score matching. Conclusions: The tricuspid regurgitation's (TR's) five-stage classifications can predict prognosis for different patients. After this classification, no difference was found between the two procedures, and open surgery is recommended for patients with acceptable general conditions.
References
Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). The American Journal of Cardiology. 1999; 83: 897–902.
Antunes MJ, Rodríguez-Palomares J, Prendergast B, De Bonis M, Rosenhek R, Al-Attar N, et al. Management of tricuspid valve regurgitation: Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease. European Journal of Cardio-Thoracic Surgery. 2017; 52: 1022–1030.
Rodés-Cabau J, Taramasso M, O'Gara PT. Diagnosis and treatment of tricuspid valve disease: current and future perspectives. Lancet. 2016; 388: 2431–2442.
Latib A, Grigioni F, Hahn RT. Tricuspid regurgitation: what is the real clinical impact and how often should it be treated? EuroIntervention. 2018; 14: AB101–AB111.
Dreyfus GD, Martin RP, Chan KMJ, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. Journal of the American College of Cardiology. 2015; 65: 2331–2336.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017; 70: 252–289.
Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, et al. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. Journal of the American College of Cardiology. 2017; 70: 2953–2960.
Morris K. Revising the Declaration of Helsinki. Lancet. 2013; 381: 1889–1890.
Taramasso M, Vanermen H, Maisano F, Guidotti A, La Canna G, Alfieri O. The growing clinical importance of secondary tricuspid regurgitation. Journal of the American College of Cardiology. 2012; 59: 703–710.
Nemoto N, Lesser JR, Pedersen WR, Sorajja P, Spinner E, Garberich RF, et al. Pathogenic structural heart changes in early tricuspid regurgitation. The Journal of Thoracic and Cardiovascular Surgery. 2015; 150: 323–330.
Medvedofsky D, Aronson D, Gomberg-Maitland M, Thomeas V, Rich S, Spencer K, et al. Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. European Heart Journal. Cardiovascular Imaging. 2017; 18: 86–94.
Taramasso M, Gavazzoni M, Pozzoli A, Dreyfus GD, Bolling SF, George I, et al. Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease. JACC. Cardiovascular Imaging. 2019; 12: 605–621.
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. Journal of the American Society of Echocardiography. 2017; 30: 303–371.
Park JB, Lee SP, Lee JH, Yoon YE, Park EA, Kim HK, et al. Quantification of Right Ventricular Volume and Function Using Single-Beat Three-Dimensional Echocardiography: A Validation Study with Cardiac Magnetic Resonance. Journal of the American Society of Echocardiography. 2016; 29: 392–401.
Sala A, Lorusso R, Bargagna M, Ascione G, Ruggeri S, Meneghin R, et al. Isolated tricuspid valve surgery: first outcomes report according to a novel clinical and functional staging of tricuspid regurgitation. European Journal of Cardio-thoracic Surgery. 2021; 60: 1124–1130.
Moraca RJ, Moon MR, Lawton JS, Guthrie TJ, Aubuchon KA, Moazami N, et al. Outcomes of tricuspid valve repair and replacement: a propensity analysis. The Annals of Thoracic Surgery. 2009; 87: 83–88; discussion 88–89.
Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M, et al. Outcome of patients undergoing isolated tricuspid repair or replacement surgery. European Journal of Cardio-Thoracic Surgery. 2022; 62: ezac230
Alqahtani F, Berzingi CO, Aljohani S, Hijazi M, Al-Hallak A, Alkhouli M. Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation. Journal of the American Heart Association. 2017; 6: e007597.
Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database. The Annals of Thoracic Surgery. 2013; 96: 1546–1552; discussion 1552.
Dreyfus GD, Corbi PJ, Chan KMJ, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? The Annals of Thoracic Surgery. 2005; 79: 127–132.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2017; 38: 2739–2791.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143: e35–e71.
Sala A, Lorusso R, Bargagna M, Ruggeri S, Buzzatti N, Scandroglio M, et al. Complicated postoperative course in isolated tricuspid valve surgery: Looking for predictors. Journal of Cardiac Surgery. 2021; 36: 3092–3099.
Kawsara A, Alqahtani F, Nkomo VT, Eleid MF, Pislaru SV, Rihal CS, et al. Determinants of Morbidity and Mortality Associated with Isolated Tricuspid Valve Surgery. Journal of the American Heart Association. 2021; 10: e018417.
Ingraham BS, Pislaru SV, Nkomo VT, Nishimura RA, Stulak JM, Dearani JA, et al. Characteristics and treatment strategies for severe tricuspid regurgitation. Heart. 2019; 105: 1244–1250.
McCarthy PM, Szlapka M, Kruse J, Kislitsina ON, Thomas JD, Liu M, et al. The relationship of atrial fibrillation and tricuspid annular dilation to late tricuspid regurgitation in patients with degenerative mitral repair. The Journal of Thoracic and Cardiovascular Surgery. 2021; 161: 2030–2040.e3.
Hahn RT. Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design. Annals of Cardiothoracic Surgery. 2017; 6: 240–247.
Taramasso M, Calen C, Guidotti A, Kuwata S, Biefer HRC, Nietlispach F, et al. Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies. Interventional Cardiology. 2017; 12: 51–55.
